- Home
- OKYO vs WHWK Comparison
OKYO vs WHWK Comparison
Compare OKYO & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | WHWK |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 95.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | OKYO | WHWK |
|---|---|---|
| Price | $2.17 | $2.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 252.8K | 129.0K |
| Earning Date | 07-18-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $1.39 |
| 52 Week High | $3.35 | $3.77 |
Technical Indicators
Market Signals| Indicator | OKYO | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 51.22 |
| Support Level | $1.97 | $2.73 |
| Resistance Level | $3.20 | $2.92 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 17.80 | 35.59 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.